Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Doxil, and Dexamethasone for High-Risk or Resistant Multiple Myeloma
NCT00458705Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2006
- Primary completion
- Apr 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00458705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458705.